Cannell & Co. Bristol Myers Squibb CO Transaction History

Cannell & Co.

$3.01 Billion
Q4 2023

A detailed history of Cannell & Co. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Cannell & Co. holds 274,317 shares of BMY stock, worth $14.2 Million. This represents 0.47% of its overall portfolio holdings.

Number of Shares

274,317

Previous 299,390 8.37%

Holding current value

$14.2 Million

Previous $17.4 Million 19.0%

% of portfolio

0.47%

Previous 0.61%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$48.48 - $57.85 $1.22 Million - $1.45 Million	-25,073 Reduced 8.37%	274,317 $14.1 Million
Q3 2023 Nov 14, 2023	SELL	$57.89 - $64.73 $641,131 - $716,884	-11,075 Reduced 3.57%	299,390 $17.4 Million
Q2 2023 Aug 09, 2023	SELL	$63.71 - $70.74 $168,831 - $187,461	-2,650 Reduced 0.85%	310,465 $19.9 Million
Q1 2023 May 08, 2023	SELL	$65.71 - $74.53 $466,803 - $529,461	-7,104 Reduced 2.22%	313,115 $21.7 Million
Q4 2022 Feb 03, 2023	SELL	$68.48 - $81.09 $243,651 - $288,518	-3,558 Reduced 1.1%	320,219 $23 Million
Q3 2022 Nov 02, 2022	SELL	$0.13 - $76.84 $421 - $248,961	-3,240 Reduced 0.99%	323,777 $23 Million
Q2 2022 Aug 08, 2022	SELL	$72.62 - $79.98 $7.31 Million - $8.05 Million	-100,685 Reduced 23.54%	327,017 $25.2 Million
Q1 2022 May 10, 2022	SELL	$61.48 - $73.72 $563,771 - $676,012	-9,170 Reduced 2.1%	427,702 $31.2 Million
Q4 2021 Feb 09, 2022	SELL	$53.63 - $62.52 $6 Million - $7 Million	-111,954 Reduced 20.4%	436,872 $27.2 Million
Q3 2021 Nov 10, 2021	SELL	$59.17 - $69.31 $5.34 Million - $6.26 Million	-90,267 Reduced 14.12%	548,826 $32.5 Million
Q2 2021 Aug 09, 2021	SELL	$61.91 - $67.42 $2.95 Million - $3.21 Million	-47,637 Reduced 6.94%	639,093 $42.7 Million
Q1 2021 May 07, 2021	SELL	$59.34 - $66.74 $759,433 - $854,138	-12,798 Reduced 1.83%	686,730 $43.4 Million
Q4 2020 Feb 11, 2021	SELL	$57.74 - $65.43 $6.8 Million - $7.71 Million	-117,836 Reduced 14.42%	699,528 $43.4 Million
Q3 2020 Nov 12, 2020	SELL	$57.43 - $63.64 $21.8 Million - $24.1 Million	-378,811 Reduced 31.67%	817,364 $49.3 Million
Q2 2020 Aug 07, 2020	BUY	$54.82 - $64.09 $19.9 Million - $23.2 Million	362,144 Added 43.42%	1,196,175 $70.3 Million
Q1 2020 May 05, 2020	SELL	$46.4 - $67.43 $4.75 Million - $6.9 Million	-102,380 Reduced 10.93%	834,031 $46.5 Million
Q4 2019 Feb 10, 2020	BUY	$49.21 - $64.19 $31 Million - $40.5 Million	630,533 Added 206.14%	936,411 $60.1 Million
Q3 2019 Nov 12, 2019	SELL	$42.77 - $50.71 $4.81 Million - $5.7 Million	-112,483 Reduced 26.89%	305,878 $15.5 Million
Q2 2019 Aug 12, 2019	SELL	$44.62 - $49.34 $4.34 Million - $4.8 Million	-97,265 Reduced 18.86%	418,361 $19 Million
Q1 2019 May 14, 2019	BUY	$45.12 - $53.8 $22.2 Million - $26.5 Million	492,572 Added 2136.6%	515,626 $24.6 Million
Q4 2018 Feb 11, 2019	SELL	$48.76 - $63.23 $3,900 - $5,058	-80 Reduced 0.35%	23,054 $1.2 Million
Q2 2018 Aug 06, 2018	SELL	$50.53 - $62.98 $145,779 - $181,697	-2,885 Reduced 11.09%	23,134 $1.28 Million
Q1 2018 May 09, 2018	SELL	$59.92 - $68.98 $5,992 - $6,898	-100 Reduced 0.38%	26,019 $1.65 Million
Q4 2017 Feb 13, 2018	SELL	$59.94 - $65.35 $5,994 - $6,534	-100 Reduced 0.38%	26,119 $1.6 Million
Q3 2017 Nov 08, 2017	BUY	$55.23 - $63.74 $1.45 Million - $1.67 Million	26,219	26,219 $1.67 Million

Others Institutions Holding BMY

# of Institutions

2,402

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $110B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cannell & Co., based on Form 13F filings with the SEC.

News

Stay updated on Cannell & Co. with notifications on news.

Account